What is the role of dasatinib in the treatment of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL)?

Updated: Jul 17, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Dasatinib is a potent, orally active inhibitor of the BCR-ABL, c-KIT and the SRC family of kinases. [49] Dasatinib is a more potent inhibitor of BCR-ABL and c-KIT than imatinib mesylate, and it is effective in patients with CML that is resistant to or intolerant of imatinib.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!